Academic literature on the topic 'San jun yi zhang dui'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'San jun yi zhang dui.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "San jun yi zhang dui"
Ji, Yinghua, Honglan Qu, Feidu Zhou, Juan Wang, Qianfu Wu, Guohua Dai, Mengyou Liu, et al. "Abstract PO2-16-08: Adjuvant Treatment Selection for County-Level Patients with HR+/HER2- Early Breast Cancer in a Real-Life Setting in China." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO2–16–08—PO2–16–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-16-08.
Full textWan, Rui, Yi Fung Chau, Jun Zhao, Zhe Liu, Mingfang Zhao, Yanqiu Zhao, Xiumei Dai, et al. "Abstract CT055: Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation." Cancer Research 84, no. 7_Supplement (April 5, 2024): CT055. http://dx.doi.org/10.1158/1538-7445.am2024-ct055.
Full textLin, Jia-Yi, Wei-Wei Zhang, Qing-Jie Li, Xue-Liang Fang, Jun-Yan Li, Shi-Wei He, Ying-Qin Li, et al. "Abstract 1113: USP18 impairs the sensitivity of radiotherapy for nasopharyngeal carcinoma by promoting the ubiquitination and nuclear translocation of TRIM29." Cancer Research 84, no. 6_Supplement (March 22, 2024): 1113. http://dx.doi.org/10.1158/1538-7445.am2024-1113.
Full textShi, Qiyun, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Shushu Wang, Guozhi Zhang, et al. "Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial." Cancer Research 83, no. 5_Supplement (March 1, 2023): OT2–22–01—OT2–22–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-22-01.
Full textLiang, Yan, Jing Liu, Tao Luo, Jia Ge, Hao Tian, Guozhi Zhang, Linjun Fan, et al. "Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial." Cancer Research 83, no. 5_Supplement (March 1, 2023): P5–10–01—P5–10–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-10-01.
Full textKim, Beom-Jun, Ze-Yi Zheng, Jonathan Lei, Matthew Holt, Anran Chen, Jianheng Peng, Diana Fandino, et al. "Abstract PO2-14-11: Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO2–14–11—PO2–14–11. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-14-11.
Full textLi, Yu-Wei, Ding Ma, Xiang-Rong Wu, Lei-Jie Dai, Shen Zhao, Yu-Zheng Xu, Xi Jin, et al. "Abstract PS09-09: Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer." Cancer Research 84, no. 9_Supplement (May 2, 2024): PS09–09—PS09–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps09-09.
Full textXie, Hui, Wei Li, Yufeng Yao, Sujie Ni, Tongbo Yi, Jinling Cheng, Qi Fang, et al. "Abstract P2-13-41: First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer." Cancer Research 82, no. 4_Supplement (February 15, 2022): P2–13–41—P2–13–41. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-13-41.
Full textShi, Qiyun, Juncheng Xuhong, Jia Ge, Feng Liu, Yang Lan, Yi Zhang, Luo Tao, Xiuwu BIan, Xiaowei Qi, and Jun Jiang. "Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–13–31—P5–13–31. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-31.
Full textShi, Qiyun, Juncheng Xuhong, Hao Tian, Yi Zhang, Jun Jiang, and Xiaowei Qi. "Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis." Cancer Research 83, no. 5_Supplement (March 1, 2023): P5–02–52—P5–02–52. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-02-52.
Full textBooks on the topic "San jun yi zhang dui"
Si da ye zhan jun zhang zhan ji shi: Zhongguo ren min jie fang jun di yi, di er, di san, di si ye zhan jun zheng zhan feng yun quan ji lu. Beijing: Zhong yang bian yi chu ban she, 2004.
Find full textQi san yi bu dui xi jun zhan yi hai yan jiu: Yi Ha'erbin shu yi liu xing wei li. Ha'erbin Shi: Heilongjiang ren min chu ban she, 2009.
Find full text1956-, Wallace David, and Wu Tianwei, eds. Qi san yi bu dui: Di er ci shi jie da zhan zhong de Riben xi jun zhan. Taibei Xian Xindian Shi: Guo shi guan bian yin, 1992.
Find full text1956-, Wallace David, and Wu Tianwei, eds. Qi san yi bu dui: Di er ci shi jie da zhan zhong di Riben xi jun zhan. Taibei Xian Xindian Shi: Guo shi guan bian yin, 1992.
Find full textZhu, Donald Knox, Liang Qing Yi, and Xia Jinbiao Yi, eds. San jiao zhou de jue qi: Mei jun san jiao zhou te zhong zuo zhan bu dui chuang shi ren hui yi lu = Delta force. Beijing: Hua xue gong ye chu ban she, 2015.
Find full textOu, Xiangjing. Yi dai yi lu, xi bu jue qi: "Shi san wu" shi qi Zhenning Buyizu Miaozu Zizhixian rong ru "yi dai yi lu" zhan lüe yan jiu. Chengdu: Xi nan jiao tong da xue chu ban she, 2016.
Find full textGuang zhou jun qu zheng zhi bu zu zhi bu. Yi xin qun: Mo fan shi jian"san ge dai biao"de xian jin zhan shi. Guang zhou: Nan fang ri bao chu ban she, 2001.
Find full textZhong gong zhong yang xuan chuan bu. Xi jin ping xin shi dai zhong guo te se she hui zhu yi si xiang san shi jiang. Beijing: Xue xi chu ban she, 2018.
Find full textYi ci cheng gong de deng lu zhan: Zhui yi Zhang Aiping jiang jun zhi hui shou ci lu hai kong san jun lian he du hai qiang gong Yijiangshan Dao. Beijing Shi: Hai chao she ying chu ban she, 2006.
Find full textJun dui yi liao bao zhang zhi du gai ge yu wei sheng gong zuo gui fan hua guan li shi yong shou ce. [Beijing Shi]: Yin sheng yin xiang chu ban she, 2004.
Find full text